BMS-933043
| Code | Size | Price |
|---|
| TAR-T26865-5mg | 5mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26865-50mg | 50mg | £2,143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26865-100mg | 100mg | £2,801.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
BMS-933043 is a Selective α7 nAChR partial agonist. BMS-933043 showed potent binding affinity to native rat (Ki = 3.3 nM) and recombinant human alpha7 nicotinic acetylcholine receptors (Ki = 8.1 nM). BMS-933043 shows agonist activity in a calcium fluorescence assay (EC50 = 23.4 nM) and whole cell voltage clamp electrophysiology (EC50 = 0.14 μM (rat) and 0.29 μM (human)).
CAS:
1221973-93-8
Formula:
C16H19N7O
Molecular Weight:
325.376
Purity:
0.98
SMILES:
C1N=C(Nc2cc(ncn2)-n2ccnc2)O[C@]11CN2CCC1CC2
References
1. Bristow LJ, Easton AE, Li YW, Sivarao DV, Lidge R, Jones KM, Post-Munson D, Daly C, Lodge NJ, Gallagher L, Molski T, Pieschl R, Chen P, Hendricson A, Westphal R, Cook J, Iwuagwu C, Morgan D, Benitex Y, King D, Macor JE, Zaczek R, Olson R. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia. PLoS One. 2016 Jul 28;11(7):e0159996. doi: 10.1371/journal.pone.0159996. PubMed PMID: 27467081; PubMed Central PMCID: PMC4965148.
2. BMS-933043, a Selective ?7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia Dalton KingChristiana IwuagwuJim CookIvar M. McDonaldRobert MateF. Christopher ZusiMatthew D. HillHaiquan FangRulin ZhaoBei WangAmy E. EastonRegina MillerDebra Post-MunsonRonald J. KnoxLizbeth GallagherRyan WestphalThaddeus MolskiJingsong FanWendy ClarkeYulia BenitexKimberley A. LentzRex DentonDaniel MorganRobert ZaczekNicholas J. LodgeLinda J. BristowJohn E. MacorRichard E. Olson Publication Date (Web): February 8, 2017 (Letter) doi: 10.1021/acsmedchemlett.7b00032